Is Cellectis S.A. (CLLS) a Buy, Sell, or Hold?
NASDAQ : CLLS
Cellectis S.A.
$2.655 USD
-$0.01 (-0.56%)
- Volume
- 6.45K
- Average Volume
- 33.74K
- Market Capitalization
- $266.61M
- P/E Ratio
- -3.92
- Dividend Yield
- 0.00%
- Price Target
- $9.00
- Year High
- $5.48
- Year Low
- $1.77
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.52
Company Overview
NASDAQ
Andre Choulika
Biotechnology
Healthcare
CLLS
216
FR
USD
Liquidity Metrics
1.38
1.52
1.52
0.26
0.00
Sales & Valuation
$72.95M
2.81
4.44
-4.78
-0.40
Profitability
-$0.68
-$67.59M
-98.69%
-101.81%
-80.61%
-23.26%
P/E Metrics
-3.92
0.04
0.04
Analyst Price Target & Rating
$9.00
$9.00
$9.00
1/5
17 Analysts
-70.50%
Poll Results
About Cellectis S.A. (NASDAQ:CLLS) Stock
Cellectis S.A. is a biotechnology firm in the clinical development stage, concentrating on the creation of immuno-oncology therapies. These therapies harness gene-edited T-cells engineered to express chimeric antigen receptors, designed to specifically identify and eliminate malignant cells. Its operations are divided into two distinct divisions: Therapeutics and Plants. The therapeutic pipeline includes several product candidates currently undergoing development. Among these is UCART19, an allogeneic T-cell therapy targeting CD19-expressing blood cancers such as acute lymphoblastic leukemia. Other key developments encompass ALLO-501 and ALLO-501A, designed for diffuse large B-cell lymphoma and follicular lymphoma in relapsed or refractory patients; ALLO-316, intended for Renal Cell Carcin ... oma; UCART123 for acute myeloid leukemia; and UCART22 for B-cell acute lymphoblastic leukemia. Furthermore, UCARTCS1 and ALLO-715 are being developed to combat multiple myeloma. Strategic partnerships form a crucial part of its operations, encompassing alliances with entities such as Allogene Therapeutics, Inc., Les Laboratoires Servier, The University of Texas M.D. Anderson Cancer Center, and Iovance Biotherapeutics. The firm also maintains a dedicated research and development collaboration with Cytovia Therapeutics, Inc. Established in 1999, Cellectis S.A. maintains its principal offices in Paris, France.
2026-07-15 08:00:00
EMERYVILLE, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Prolynx, a biotechnology company developing a next-generation portfolio of ultra-long-acting medicines for obesity and related metabolic conditions, today announced two additions to its executive leadership team: Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer.
Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026
2026-06-25 16:30:00
NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today its shareholders general meeting at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France.
2026-06-11 02:40:00
NEW YORK, June 11, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, presents final Phase 1 data from the BALLI-01 clinical trial evaluating lasme-cel, a CD22 directed allogeneic CAR-T therapy, in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL), and preliminary data from the NATHALI-01 study evaluating eti-cel, a dual CD20 and CD22 directed CAR-T in relapsed/refractory B-cell non Hodgkin lymphoma (r/r B-NHL), at the European Hematology Association (EHA) 2026 Annual Congress.
2026-06-09 16:30:00
NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to lasmecabtagene timgedleucel (lasme-cel), its CD22-targeting allogeneic CAR-T cell therapy product candidate, for the treatment of patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL).
Monthly information on share capital and company voting rights
2026-06-03 16:30:00
PARIS, June 03, 2026 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 Date Total number of shares in the capital Total number of voting rights 05/31/2026 100,691,658 106,134,467 For further information on Cellectis, please contact: Media contacts: Pascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14 33, [email protected] Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93 Investor Relations contact: Arthur Stril, Chief Financial Officer & Chief Business Officer, [email protected] Attachments Voting_Rights_PR_May_2026_EN
Cellectis' Annual Shareholders General Meeting to be Held on June 25, 2026
2026-05-20 16:30:00
NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it will hold its annual general meeting on June 25, 2026 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France.
Cellectis’ Annual Shareholders General Meeting to be Held on June 25, 2026
2026-05-20 16:30:00
NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it will hold its annual general meeting on June 25, 2026 at 2:30 p.
Cellectis to Present Clinical Data on Lasme-cel and Eti-cel at EHA 2026 Annual Congress
2026-05-12 09:30:00
NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced upcoming presentations on the BALLI-01 and NATHALI-01 clinical trials, at the European Hematology Association (EHA) annual congress, on June 11-14, 2026, in Stockholm, Sweden.
Frequently Asked Questions
-
What is the current Cellectis S.A. (CLLS) stock price?
-
Cellectis S.A.(NASDAQ:CLLS) stock price is $2.655 in the last trading session. During the trading session, CLLS stock reached the peak price of $5.48 while $1.77 was the lowest point it dropped to. The percentage change in CLLS stock occurred in the recent session was --0.56% while the dollar amount for the price change in CLLS stock was -$0.01.
-
CLLS's industry and sector of operation?
-
The NASDAQ listed CLLS is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CLLS?
-
Stephan Reynier | Chief Regulatory & Pharmaceutical Compliance Officer
Kyung Nam-Wortman | Executive Vice President & Chief Human Resources Officer
Jean Charles Epinat | Chief Technological Officer
Valerie Cros | Principal Financial Officer & Principal Accounting Officer
Marie-Bleuenn Terrier | General Counsel & Secretary of the Board of Directors -
How many employees does CLLS have?
-
Number of CLLS employees currently stands at 216. CLLS operates from 8, rue de la Croix Jarry, Paris, IF 75013, FR.
-
Link for CLLS official website?
-
Official Website of CLLS is: https://www.cellectis.com
-
How do I contact CLLS?
-
CLLS could be contacted at phone #33 1 81 69 16 00 and can also be accessed through its website. CLLS operates from 8, rue de la Croix Jarry, Paris, IF 75013, FR.
-
How many shares of CLLS are traded daily?
-
The average number of CLLS shares traded daily for last 3 months was 33.74K.
-
What is the market cap of CLLS currently?
-
The market value of CLLS currently stands at $266.61M with its latest stock price at $2.655